Mankind Pharma Ltd. (MANKIND) AI Stock Analysis

• Market Cap: ₹899.73B
• Dividend Yield: 0.05%
• Average Volume (3M): 10.08K
• Price to Earnings (P/E): 51.1
• Beta (1Y): 0.58
• Revenue Growth: 23.22%
• EPS Growth: -19.19%
• Country: IN
• Employees: 19,540
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 12.40
• Shares Outstanding: 412,805,080
• 10 Day Avg. Volume: 5,924
• 30 Day Avg. Volume: 10,081
• PEG Ratio: 16.80
• Price to Book (P/B): 6.94
• Price to Sales (P/S): 8.15
• P/FCF Ratio: 50.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹2,783.33
• Price Target Upside: 27.70% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: ₹2,365.00 ▲(8.51% Upside)

Mankind Pharma's strong financial performance is the most significant positive factor, showcasing robust growth and operational efficiency. However, the stock's technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation, which are key risks impacting the overall score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Profit Margins

High profit margins reflect efficient cost management and pricing power, contributing to sustainable profitability.

Cash Flow Generation

Strong cash flow generation supports reinvestment in growth opportunities and provides financial flexibility.

Negative Factors

EPS Decline

A decline in EPS suggests potential challenges in maintaining profitability, which could affect investor confidence and future growth.

Valuation Concerns

High valuation ratios can limit upside potential and may lead to corrections if growth expectations are not met.

Bearish Momentum

Prolonged bearish momentum could impact investor sentiment and hinder stock performance, affecting capital raising ability.

Mankind Pharma Ltd. Business Overview & Revenue Model

Company Description

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. Mankind Pharma Limited was founded in 1986 and is based in New Delhi, India.

How the Company Makes Money

Mankind Pharma generates revenue primarily through the sale of its pharmaceutical and healthcare products. The company has a robust revenue model that includes direct sales to healthcare providers, retail pharmacies, and hospitals, complemented by a strong export business. Key revenue streams include prescription medications, OTC products, and nutraceuticals. Additionally, Mankind engages in strategic partnerships and collaborations with other pharmaceutical companies and distributors, enhancing its market reach and product offerings. The company's focus on innovation and expanding its product portfolio, particularly in high-demand therapeutic areas, significantly contributes to its earnings.

Mankind Pharma Ltd. Financial Statement Overview

Summary

Mankind Pharma has demonstrated strong financial performance with robust revenue growth, impressive profit margins, and effective operational efficiency. The balance sheet is stable with low leverage, and cash flow management is sound, indicating a healthy and sustainable growth trajectory.

Income Statement

Mankind Pharma has shown robust revenue growth with a significant increase of 18.14% in 2025 compared to 2024. The company's gross profit margin remains strong at 71.41%, and the net profit margin is healthy at 16.31%. EBIT and EBITDA margins are impressive at 49.37% and 24.73%, respectively, showcasing effective operational efficiency.

Balance Sheet

The debt-to-equity ratio is well managed at 0.59, indicating prudent leverage. Return on equity is commendable at 13.89%, reflecting efficient use of equity capital. The equity ratio is strong at 51.62%, ensuring financial stability and low risk. The company's balance sheet reflects a solid financial position with a strong equity base.

Cash Flow

The company exhibits a sound cash flow position with a free cash flow growth rate of 10.32%. The operating cash flow to net income ratio stands at 1.21, demonstrating good cash flow generation capability. The free cash flow to net income ratio is also robust at 0.98, indicating strong cash flow relative to net earnings.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	129.56B	122.07B	103.35B	87.43B	77.82B	62.14B
Gross Profit	84.65B	87.18B	70.14B	33.88B	53.12B	43.89B
EBITDA	34.10B	30.18B	28.09B	20.27B	21.47B	18.17B
Net Income	18.93B	19.91B	19.13B	12.82B	14.33B	12.65B
Balance Sheet
Total Assets	0.00	277.60B	119.63B	97.15B	91.48B	63.73B
Cash, Cash Equivalents and Short-Term Investments	25.25B	22.45B	34.56B	15.29B	12.79B	20.04B
Total Debt	0.00	85.11B	2.07B	1.70B	8.73B	2.41B
Total Liabilities	-145.68B	131.91B	23.87B	20.67B	28.31B	15.10B
Stockholders Equity	145.68B	143.32B	93.63B	74.35B	61.55B	47.22B
Cash Flow
Free Cash Flow	0.00	19.53B	17.70B	9.53B	-14.26B	8.25B
Operating Cash Flow	0.00	24.13B	21.52B	17.85B	9.20B	11.37B
Investing Cash Flow	0.00	-126.92B	-20.82B	-10.54B	-13.69B	-12.22B
Financing Cash Flow	0.00	102.33B	52.66M	-7.40B	6.05B	-78.11M

Mankind Pharma Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2179.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MANKIND, the sentiment is Negative. The current price of 2179.55 is below the 20-day moving average (MA) of 2215.91, below the 50-day MA of 2325.10, and below the 200-day MA of 2423.39, indicating a bearish trend. The MACD of -43.31 indicates Negative momentum. The RSI at 35.34 is Neutral, neither overbought nor oversold. The STOCH value of 24.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MANKIND.

Mankind Pharma Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	74 Outperform	₹693.30B	20.26	―	0.33%	7.33%	-3.79%
LUPIN	72 Outperform	₹965.64B	22.32	―	0.57%	15.49%	64.37%
ZYDUSLIFE	72 Outperform	₹934.84B	19.00	―	1.18%	14.01%	14.62%
CIPLA	68 Neutral	₹1.23T	22.52	―	0.86%	6.93%	21.55%
TORNTPHARM	66 Neutral	₹1.28T	59.93	―	0.84%	9.11%	18.76%
MANKIND	59 Neutral	₹899.73B	51.09	―	0.05%	23.22%	-19.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Mankind Pharma Ltd. Corporate Events

Mankind Pharma Challenges GST Order on Subsidiary Merger

Mankind Pharma Ltd. has announced that it received an order from the Office of the Assistant Commissioner, Cuttack, regarding a penalty imposed on its wholly owned subsidiary, Lifestar Pharma Private Limited, which has since merged with the company. The order pertains to alleged mismatches in ITC figures in GST returns for the financial years 2018-19 and 2019-20. Mankind Pharma views the order as arbitrary and plans to appeal, asserting that there is no material impact on its financials or operations.

Mankind Pharma Reports Strong Financial Performance for Q2 and H1 2025

Mankind Pharma Ltd. announced its unaudited financial results for the quarter and half-year ending September 30, 2025. The company reported strong revenue and profit figures, indicating robust operational performance. This announcement is likely to reinforce Mankind Pharma’s market position and could have positive implications for its stakeholders.

Mankind Pharma Receives ESG Rating Score of 69

Mankind Pharma Ltd. has received an ESG rating score of 69 from CFC Finlease Private Limited, an independent SEBI-registered ESG rating provider. This rating, which was not solicited by the company, reflects its performance in environmental, social, and governance aspects, potentially impacting its reputation and stakeholder perceptions.

Mankind Pharma Schedules Investor Conference Call for Q2 & H1 FY26

Mankind Pharma Limited has announced an upcoming investor conference call scheduled for November 6, 2025, to discuss the company’s financial performance for the second quarter and first half of the fiscal year 2026. This event will provide stakeholders with insights into the company’s business performance and strategic direction, potentially impacting investor confidence and market positioning.

Mankind Pharma Reports No Share Dematerialisation Requests for Q3 2025

Mankind Pharma Limited has announced that it has not received any requests for dematerialisation or rematerialisation of shares for the quarter ending September 30, 2025. This update, certified by KFin Technologies Limited, aligns with the company’s adherence to SEBI (Depositories and Participants) Regulations, 2018, ensuring transparency and compliance in its share management practices.

Mankind Pharma Ltd. Sees Withdrawal of CGST Penalty

Mankind Pharma Ltd. announced that the penalty of ₹2,90,70,363 imposed by the CGST Commissionerate, Meerut, for the financial years 2017-18 to 2021-22, has been withdrawn following an appeal. This development is likely to have a positive impact on the company’s financial standing and may enhance its reputation among stakeholders by demonstrating effective legal and regulatory compliance.

Mankind Pharma to Engage with Investors at Jefferies India Forum

Mankind Pharma Ltd. has announced its participation in the upcoming Jefferies 4th India Forum, scheduled for September 17, 2025, in Gurugram. The event will include one-on-one and group meetings, allowing the company’s management to engage with investors. This participation underscores Mankind Pharma’s proactive approach to investor relations and its commitment to transparency, although no unpublished price-sensitive information will be disclosed during the conference.